Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead multiple sclerosis drug candidate, Lucid-MS, toward human trials while simultaneously growing commercial revenue from its unbuzzd product, according to Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent interview on the BioMedWire Podcast.
Durkacz detailed the company's strategy for Lucid-MS, a patented new chemical entity designed to address mobility damage associated with multiple sclerosis. The company has filed an investigational new drug application for a Phase 2 clinical trial, which would represent the first administration of Lucid-MS to human MS patients. This milestone is critical for Quantum BioPharma, as it transitions from preclinical success—where Lucid-MS showed ability to prevent and reverse myelin degradation—to clinical validation. The potential impact of a therapy that could restore myelin in MS patients is significant, given the debilitating nature of the disease and the limited treatment options available.
Complementing its clinical pipeline, Quantum BioPharma has commercialized unbuzzd, a product designed to accelerate alcohol metabolism. The company spun out the over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% equity stake as of March 31, 2026. The agreement also includes royalty payments: 7% of sales until total payments reach $250 million, then 3% in perpetuity. This structure provides Quantum BioPharma with a steady revenue stream that can fund its clinical programs without diluting shareholder value. Durkacz emphasized that unbuzzd represents a tangible commercial opportunity in the alcohol-misuse market, a sector with substantial demand.
The dual focus on clinical-stage drug development and commercial products positions Quantum BioPharma uniquely in the biopharmaceutical landscape. While many early-stage biotechs rely solely on fundraising, Quantum BioPharma's strategy of generating revenue from unbuzzd offers financial flexibility and reduces dependence on capital markets. This approach could accelerate the development of Lucid-MS and other pipeline candidates targeting neurodegenerative and metabolic disorders.
Investors should note the forward-looking statements associated with these developments. The company faces risks common to clinical-stage biopharmaceuticals, including regulatory hurdles and trial outcomes. However, the progress of Lucid-MS toward Phase 2 trials and the commercial traction of unbuzzd provide clear catalysts. For more details, the full podcast episode is available at https://ibn.fm/IWnPQ. Updates on Quantum BioPharma are available in the company's newsroom at https://ibn.fm/QNTM.
